Sugi Predict

Sugi Predict / Compounds / SCHEMBL1872809

SCHEMBL1872809

SCHEMBL1872809

COC(=O)c1cc2ccccc2c(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.53
▸ GAA P10253 5/20 0.53
▸ ALDH1A1 P00352 6/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ HTT P42858 1/20 0.53
▸ PADI4 Q9UM07 1/20 0.53
▸ HPGD P15428 5/20 0.51
▸ PARP1 P09874 1/20 0.51
▸ GLA P06280 2/20 0.50
▸ CDC25B P30305 3/20 0.49
▸ THRB P10828 3/20 0.49
▸ XDH P47989 1/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ APAF1 O14727 2/20 0.48
▸ CASP3 P42574 2/20 0.48
▸ SENP8 Q96LD8 2/20 0.48
▸ SENP7 Q9BQF6 2/20 0.48
▸ SENP6 Q9GZR1 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30853483 1.00 KDM4E (0.53) KDM4EGAAALDH1A1NPSR1HTT
SCHEMBL15367087 0.83 KDM4E (0.63) KDM4EGAAALDH1A1HTTHPGD
SCHEMBL14743916 0.80 CHEK1 (0.48) KDM4EGAAPARP1GLACYP1A2
SCHEMBL19953791 0.80 CHEK1 (0.48) KDM4EGAAALDH1A1NPSR1HTT
SCHEMBL29430150 0.80 HPGD (0.62) KDM4EGAAALDH1A1HPGDPARP1
SCHEMBL2815600 0.80 HPGD (0.62) KDM4EGAAALDH1A1HPGDPARP1
SCHEMBL8985899 0.79 ALDH1A1 (0.67) KDM4EGAAALDH1A1NPSR1HPGD
SCHEMBL175459 0.78 LOXL2 (0.54) KDM4EGAAALDH1A1HPGDPARP1
SCHEMBL519591 0.78 KDM4E (0.69) KDM4EGAAALDH1A1HPGDXDH
SCHEMBL29751000 0.78 LOXL2 (0.54) KDM4EGAAALDH1A1HPGDPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486251-B2 CBP/EP300 inhibitor and use thereof PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2025-12-02 — — US disclosed
CN-115397822-B CBP/EP300 inhibitors and uses thereof 南京药石科技股份有限公司 2024-04-16 — — CN disclosed
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2023-05-25 — — US disclosed
EP-4140996-A1 CBP/EP300 INHIBITOR AND USE THEREOF PHARMABLOCK SCIENCES (NANJING), INC. (CN) 2023-03-01 — — EP disclosed
CN-115397822-A CBP/EP300 inhibitors and uses thereof 南京药石科技股份有限公司 2022-11-25 — — CN disclosed
WO-2021213521-A1 CBP/EP300 INHIBITOR AND USE THEREOF 南京药石科技股份有限公司 (CN) 2021-10-28 — — WO disclosed
WO-2018048930-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 — — WO disclosed
US-9475822-B2 Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-25 — — US disclosed
CN-102812014-B The purposes of novel 9 oxime derivate and the allosteric modulators as metabotropic glutamate receptor thereof DOMAIN THERAPEUTICS (FR) 2016-01-20 — — CN disclosed
US-9212149-B2 Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-15 — — US disclosed
WO-2012003147-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-01-05 — — WO disclosed
US-20110301208-A1 VIRAL AND FUNGAL INHIBITORS WICHITA STATE UNIVERSITY (US) 2011-12-08 — — US disclosed
US-20110301208-A1 VIRAL AND FUNGAL INHIBITORS WICHITA STATE UNIVERSITY (US) 2011-12-08 — — US disclosed
WO-2011051478-A1 NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS DOMAIN THERAPEUTICS (FR) 2011-05-05 — — WO disclosed
WO-2010125343-A1 COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS QUEEN MARY AND WESTFIELD COLLEGE (GB) 2010-11-04 — — WO disclosed
US-20090023729-A1 Trisubstituted amine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-22 — — US disclosed
US-20080027050-A1 Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-31 — — US disclosed
EP-1740551-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR Takeda Pharmaceutical Company Limited (JP) 2007-01-10 — — EP disclosed
WO-2005105760-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-10 — — WO disclosed
US-5728712-A 3,4-disubstituted-phenylsulphonamides and their therapeutic use CHIROSCIENCE LIMITED (GB) 1998-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301208-A1 VIRAL AND FUNGAL INHIBITORS HAVCR2, ZC3HAV1, ERG28 KDM4E 2812/4885GAA 79/4885ALDH1A1 2480/4885
US-20080027050-A1 Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) MMP13, HDAC11, HDAC1 KDM4E 1156/4885GAA 4317/4885ALDH1A1 1042/4885
US-20230159497-A1 CBP/EP300 INHIBITOR AND USE THEREOF EP300, CREBBP, BPTF KDM4E 440/4885GAA 4668/4885ALDH1A1 2314/4885
US-12486251-B2 CBP/EP300 inhibitor and use thereof EP300, CREBBP, BPTF KDM4E 440/4885GAA 4668/4885ALDH1A1 2314/4885
US-20090023729-A1 Trisubstituted amine compound CETP, MTTP, APOB KDM4E 418/4885GAA 1887/4885ALDH1A1 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.